Advice

following an abbreviated submission:

eptinezumab (Vyepti®) is accepted for restricted use within NHSScotland.

Indication under review: for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.

Eptinezumab provides an additional treatment choice in the therapeutic class of calcitonin gene-related peptide (CGRP) inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Download detailed advice736KB (PDF)

Download

Medicine details

Medicine name:
eptinezumab (Vyepti)
SMC ID:
SMC2547
Indication:

Prophylaxis of migraine in adults who have at least 4 migraine days per month.

Pharmaceutical company
Lundbeck Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published
13 February 2023